Molecular Pathology

Molecular Pathology

The Vancouver Prostate Centre's Molecular Pathology core facility offers clinical grade, high throughput analytical services with fast turnaround times. Our unique access to live human tumour tissues allows for identification of new tumour targets, validation of function, and the development of tumour models in our Functional Genomics core facility.

Cellular and Molecular Imaging Suite

The Cellular and Molecular Imaging Suite supports the use of state-of-the-art bright field, laser scanning and spinning disk confocal fluorescent microscopic imaging technologies for cellular and subcellular localization studies of molecules and pathways critical to prostate cancer cell growth and survival. These imaging systems are used to monitor cellular expression and localization of proteins, which enable studies of the role of these factors in regulation of tumour cell growth, survival and differentiation signalling pathways.

Bio-Repository – A Unique Research Resource

The Vancouver Prostate Centre has a tumour bank that contains well over 2000 prostate cancer specimens (both fresh frozen and paraffin embedded). This tumour bank has an integrated database that is overseen by a full-time coordinator, along with a full-time research pathologist and staff.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember Foundation 2018

Movember 2018

The Movember Foundation's fundraiser runs from November 1 to 30.  Click here to donate to The Vancouver Prostate Centre team as we join teams across Canada to raise funds for men's health research in the areas of prostate cancer, testicular cancer, mental health and suicide prevention.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development